DK0775704T3 - Krystallinsk hydrochlorid af (R)-(-)-2-{N-[4-(1,1-dioxido-3-oxo-2,3-dihydrobenziosothiazol-2-yl)-butyl]-aminomethyl}-chroman - Google Patents

Krystallinsk hydrochlorid af (R)-(-)-2-{N-[4-(1,1-dioxido-3-oxo-2,3-dihydrobenziosothiazol-2-yl)-butyl]-aminomethyl}-chroman

Info

Publication number
DK0775704T3
DK0775704T3 DK96118043T DK96118043T DK0775704T3 DK 0775704 T3 DK0775704 T3 DK 0775704T3 DK 96118043 T DK96118043 T DK 96118043T DK 96118043 T DK96118043 T DK 96118043T DK 0775704 T3 DK0775704 T3 DK 0775704T3
Authority
DK
Denmark
Prior art keywords
dihydrobenziosothiazol
dioxido
chroman
aminomethyl
oxo
Prior art date
Application number
DK96118043T
Other languages
English (en)
Inventor
Alfons Dr Grunenberg
Oliver Dr Brehm
Michael Dr Conrad
Dietrich Dr Seidel
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag filed Critical Bayer Ag
Application granted granted Critical
Publication of DK0775704T3 publication Critical patent/DK0775704T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
DK96118043T 1995-11-22 1996-11-11 Krystallinsk hydrochlorid af (R)-(-)-2-{N-[4-(1,1-dioxido-3-oxo-2,3-dihydrobenziosothiazol-2-yl)-butyl]-aminomethyl}-chroman DK0775704T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19543478A DE19543478A1 (de) 1995-11-22 1995-11-22 Kristallines Hydrochlorid von {(R)-(-)-2- N-[4-(1,1-Dioxido-3-oxo-2,3-dihydrobenzisothiazol-2-yl)-buytl]-aminomethyl}-chroman

Publications (1)

Publication Number Publication Date
DK0775704T3 true DK0775704T3 (da) 2001-07-23

Family

ID=7778081

Family Applications (1)

Application Number Title Priority Date Filing Date
DK96118043T DK0775704T3 (da) 1995-11-22 1996-11-11 Krystallinsk hydrochlorid af (R)-(-)-2-{N-[4-(1,1-dioxido-3-oxo-2,3-dihydrobenziosothiazol-2-yl)-butyl]-aminomethyl}-chroman

Country Status (32)

Country Link
US (1) US5830908A (da)
EP (1) EP0775704B1 (da)
JP (1) JPH09143180A (da)
KR (1) KR970027079A (da)
CN (1) CN1086703C (da)
AR (1) AR004961A1 (da)
AT (1) ATE201872T1 (da)
AU (1) AU712922B2 (da)
BR (1) BR9605646A (da)
CA (1) CA2190700A1 (da)
CZ (1) CZ289730B6 (da)
DE (2) DE19543478A1 (da)
DK (1) DK0775704T3 (da)
EE (1) EE9600183A (da)
ES (1) ES2159342T3 (da)
GR (1) GR3036505T3 (da)
HU (1) HUP9603237A3 (da)
IL (1) IL119647A (da)
MX (1) MX9605741A (da)
MY (1) MY132473A (da)
NO (1) NO307340B1 (da)
NZ (1) NZ299780A (da)
PL (1) PL317090A1 (da)
PT (1) PT775704E (da)
RU (1) RU2181723C2 (da)
SG (1) SG44989A1 (da)
SI (1) SI0775704T1 (da)
SK (1) SK150096A3 (da)
TR (1) TR199600930A2 (da)
TW (1) TW449595B (da)
UA (1) UA45338C2 (da)
ZA (1) ZA969753B (da)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5854217A (en) * 1992-09-28 1998-12-29 Bearsden Bio, Inc. Allosteric modulators of the NMDA receptor and their use in the treatment of CNS disorders and enhancement of CNS function
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US7501426B2 (en) 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
DE102005035891A1 (de) 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
EA030606B1 (ru) 2006-05-04 2018-08-31 Бёрингер Ингельхайм Интернациональ Гмбх Способы приготовления лекарственного средства, содержащего полиморфы
KR101610005B1 (ko) * 2007-08-17 2016-04-08 베링거 인겔하임 인터내셔날 게엠베하 Ｆａｂ 관련 질환의 치료에 사용하기 위한 푸린 유도체
PE20140960A1 (es) 2008-04-03 2014-08-15 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
PE20100156A1 (es) * 2008-06-03 2010-02-23 Boehringer Ingelheim Int Tratamiento de nafld
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
BRPI0916997A2 (pt) 2008-08-06 2020-12-15 Boehringer Ingelheim International Gmbh Inibidor de dpp-4 e seu uso
EA031225B1 (ru) * 2008-08-15 2018-12-28 Бёрингер Ингельхайм Интернациональ Гмбх Ингибиторы дпп-4 для заживления ран
EP2344195A2 (en) 2008-09-10 2011-07-20 Boehringer Ingelheim International GmbH Combination therapy for the treatment of diabetes and related conditions
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
BRPI0923121A2 (pt) 2008-12-23 2015-08-11 Boehringer Ingelheim Int Formas salinas de compostos orgânico
TW201036975A (en) 2009-01-07 2010-10-16 Boehringer Ingelheim Int Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy
ES2760917T3 (es) 2009-11-27 2020-05-18 Boehringer Ingelheim Int Tratamiento de pacientes diabéticos genotipificados con inhibidores DPP-IV como la linagliptina
JP6034781B2 (ja) 2010-05-05 2016-11-30 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 併用療法
EA201991014A1 (ru) 2010-06-24 2019-09-30 Бёрингер Ингельхайм Интернациональ Гмбх Лечение диабета
US9034883B2 (en) 2010-11-15 2015-05-19 Boehringer Ingelheim International Gmbh Vasoprotective and cardioprotective antidiabetic therapy
MX366629B (es) 2011-07-15 2019-07-17 Boehringer Ingelheim Int Quinazolinas sustituidas, su preparación y su uso en composiciones farmacéuticas.
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
EP3685839A1 (en) 2012-05-14 2020-07-29 Boehringer Ingelheim International GmbH Linagliptin for use in the treatment of albuminuria and kidney related diseases
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
US9526728B2 (en) 2014-02-28 2016-12-27 Boehringer Ingelheim International Gmbh Medical use of a DPP-4 inhibitor
JP2019517542A (ja) 2016-06-10 2019-06-24 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング リナグリプチンおよびメトホルミンの組合せ

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3901814A1 (de) 1988-07-28 1990-02-01 Bayer Ag Substituierte aminomethylzetraline sowie ihre heterocyclischen analoga
US5300523A (en) * 1988-07-28 1994-04-05 Bayer Aktiengesellschaft Substituted aminomethyltetralins and their heterocyclic analogues
DE4138756A1 (de) * 1991-11-26 1993-05-27 Troponwerke Gmbh & Co Kg Kombination mit neuroprotektiver wirkung

Also Published As

Publication number Publication date
TW449595B (en) 2001-08-11
MY132473A (en) 2007-10-31
CN1086703C (zh) 2002-06-26
HU9603237D0 (en) 1997-01-28
NZ299780A (en) 1998-09-24
UA45338C2 (uk) 2002-04-15
MX9605741A (es) 1997-05-31
ATE201872T1 (de) 2001-06-15
NO307340B1 (no) 2000-03-20
AR004961A1 (es) 1999-04-07
PT775704E (pt) 2001-09-28
NO964950L (no) 1997-05-23
SI0775704T1 (en) 2001-08-31
DE59607040D1 (de) 2001-07-12
CZ342896A3 (en) 1997-06-11
EP0775704B1 (de) 2001-06-06
EE9600183A (et) 1997-06-16
IL119647A (en) 1999-12-22
AU7177296A (en) 1997-05-29
KR970027079A (ko) 1997-06-24
ZA969753B (en) 1997-03-25
CZ289730B6 (cs) 2002-03-13
PL317090A1 (en) 1997-05-26
BR9605646A (pt) 1998-08-18
CA2190700A1 (en) 1997-05-23
GR3036505T3 (en) 2001-11-30
AU712922B2 (en) 1999-11-18
CN1152574A (zh) 1997-06-25
DE19543478A1 (de) 1997-05-28
NO964950D0 (no) 1996-11-21
US5830908A (en) 1998-11-03
EP0775704A1 (de) 1997-05-28
HUP9603237A2 (hu) 1998-01-28
RU2181723C2 (ru) 2002-04-27
ES2159342T3 (es) 2001-10-01
IL119647A0 (en) 1997-02-18
HUP9603237A3 (en) 1998-12-28
JPH09143180A (ja) 1997-06-03
TR199600930A2 (tr) 1997-06-21
SK150096A3 (en) 1997-08-06
SG44989A1 (en) 1997-12-19

Similar Documents

Publication Publication Date Title
DK0775704T3 (da) Krystallinsk hydrochlorid af (R)-(-)-2-{N-[4-(1,1-dioxido-3-oxo-2,3-dihydrobenziosothiazol-2-yl)-butyl]-aminomethyl}-chroman
DE69621777T2 (de) Formen von paroxetin hydrochlorid
NO990854L (no) Substituerte N-[(aminiminmetyl- eller aminmetyl)fenyl]-propylamider
ID17275A (id) N-[4-(heteroarilmetil)fenil]-heteroarilamina
EE9900053A (et) 4-(5-metüül-3-fenüülisoksasool-4-üül)benseensulfoonamiidi kristalliline vorm
DE69812633T2 (de) Von nitrone- oder nitroso-verbindungen abgeleitete alkoxyaminverbindungen-enthaltende polymerisierbare zusammensetzungen
NO965084D0 (no) N-[3(3-cyanopyrazol[1,5-aÅpyrimidin-7-yl)fenylÅ-N-etyl-acetamid
EE200100135A (et) EtO2C-CH2-(R)Cgl-Aze-Pab-OH kristalsed vormid
DE69613377D1 (de) 2-(4-substituierte)-benzylamino-2-methyl-propanamid-derivate
WO1999012570A3 (en) Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents
FR2758328B1 (fr) Nouvelles amines aromatiques derivees d'amines cycliques utiles comme medicaments
FR2735374B3 (fr) Nouvelle bille amelioree
NO20006350D0 (no) Derivater av 3-(2-okso-[1,3']bipyrrolidinyl-3-ylidenmetyl)- cephemer
DE69908951D1 (de) Kristallformen von osanetant
MA25653A1 (fr) Derives d'amides heterocycliques.
EE05381B1 (et) MeetodÁ2-(asendatudÁfenl)-2-hdroksetlkarbamaatideÁvalmistamiseks,ÁselleksÁvajalikudÁvahehendidÁningÁsaadudÁkarbamaatideÁpolmorfsedÁvormid
NO20003145D0 (no) FremgangsmÕte for fremstilling av paroxetine-hydroklorid
BR9606610A (pt) Herbicidas n-(1-etil-4-pirazolil) triazolazinasulfonamida
DE69625379T2 (de) Salze des n-[4-oxo-2-(1h-tetrazoyl-5-yl)-4h-1-benzopyran-8-yl]-4-(4-phenylbutoxy)benzamids
DK0880352T3 (da) Stabilisering af naloxon-hydrochlorid